dPCR and qPCR Market Analysis, Size, Growth Drivers and Future Outlook

dPCR and qPCR Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment [Quantitative PCR (qPCR) and Digital PCR (dPCR)], Product (Reagents & Consumables, Instruments, and Software & Services), Application (Research Application, Clinical Application, and Forensic Application), End User (Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research Laboratories and Academic Institutes, Forensic Laboratories, and Clinical Research Organizations), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

Publication Month : Nov 2023

  • Report Code : TIPHE100000817
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 159
Inquire Before Buy

PRICING

$5190

$4152

[Research Report] The dPCR and qPCR market size is projected to grow from US$ 8,976.99 million in 2022 to US$ 18,230.74 million by 2030; it is projected to record a CAGR of 9.3% during 2022–2030.

Market Insights and Analyst View:

Quantitative PCR (qPCR) and digital PCR (dPCR) are the two main categories of PCR technologies. dPCR is used to assess the appropriate dosages for gene and cell therapies and detect circulating tumor DNA in cancer patients. qPCR calculates PCR amplification simultaneously as the reaction proceeds. dPCR and qPCR are extensively used diagnostic techniques in diverse sectors such as research, pharmaceuticals, and biotechnology, offering a wide range of applications. The growing demand for molecular testing is fueled by technological advancements in PCR systems and the growing need for accurate and reliable detection of cancer biomarkers. Additionally, the increasing demand for personalized medicine among the population, improving genomics research, and the growing incidence of infectious diseases propel the dPCR and qPCR market growth.

Growth Drivers:

According to the National Organization's information on genetic conditions or congenital disabilities, though individual genetic disorders are rare, collectively, they comprise over 15,500 people diagnosed with genetic disorders. In 2022, a report by MJH Life Sciences (US) estimates that 300,000 newborns worldwide are born with sickle cell disease every year, accounting for ∼ 5% of the global population. In the US, it is one of the most prevalent genetic conditions. Also, 1 in 500 African Americans is affected by sickle cell disease, and ∼ 1 in 12 of them suffers from the autosomal recessive mutation, according to the CDC. In June 2020, as per Novartis AG (Switzerland) report, ∼15,000 individuals have sickle cell disease, and 270 newborns are diagnosed with the condition every year. Furthermore, the disease is most prevalent in emerging nations such as India. Among India's tribal communities, ∼18 million people are affected by sickle cell trait (SCT), and 1.4 million people are suffering from sickle cell disease (SCD). The adoption of digital PCR is improving as pathologists are trying to track the use of this technology to target various specific DNA sequences and diagnose and design various clinical tests. Digital PCR can target specific DNA sequences in just one molecule of DNA. This new tool allows researchers to isolate rare genetic mutations that are too difficult to segregate with real-time PCR.

The COVID-19 outbreak had a significant effect on the polymerase chain reaction market growth. The growing demand in the clinical diagnostic market has a favorable effect on the PCR industry. Nearly all diagnostic tests used RT-PCR to test people having symptoms of COVID-19 and were urged by healthcare experts to undergo a diagnostic test, while the authorities have not endorsed viral culture tests. The majority of biotech and pharmaceutical businesses were concentrating their efforts on research and development divisions to find novel compounds or therapy approaches for COVID-19. In February 2022, Roche added the Cobas 5800 System, a newly released molecular laboratory instrument, to its COVID-19 PCR portfolio for use in nations that accept the CE certification. These products include the cobas SARS-CoV-2 and influenza A/B tests, as well as the cobas SARS-CoV-2 qualitative test. By offering uniform performance and efficiency across low-, medium--, and high-volume molecular laboratory testing needs, these products broaden the Roche Diagnostics molecular portfolio offering. Additionally, healthcare organizations with limited space or resources can have comprehensive access owing to the new, compact Cobas 5800 System. Better testing accessibility will result from this in nations or settings where larger equipment cannot be accommodated due to a lack of resources or space.

Thus, the increasing incidence of genetic and infectious diseases in which dPCR and qPCR techniques can be used for diagnosis and treatments drives the growth of the dPCR and qPCR market.  

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

dPCR and qPCR Market: Strategic Insights

dpcr-and-qpcr-market
Market Size Value inUS$ 8,976.99 million in 2022
Market Size Value byUS$ 18,230.74 million by 2030
Growth rateCAGR of 9.3% from 2022 to 2030
Forecast Period2022-2030
Base Year2022
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Report Segmentation and Scope:

The dPCR and qPCR market is segmented on the basis of treatment, product, application, end user, and geography. Based on treatment, the dPCR and qPCR market is bifurcated into quantitative PCR and digital PCR. In terms of product, the dPCR and qPCR market is segmented into reagents & consumables, instruments, and software & services. By application, the dPCR and qPCR market is segmented into research application, clinical application, and forensic application. In terms of end user, the dPCR and qPCR market is segmented into hospitals and diagnostic centers, research laboratories and academic institutes, pharmaceutical and biotechnology companies, forensic laboratories, and clinical research organizations. The dPCR and qPCR market, based on geography, is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Segmental Analysis:

The dPCR and qPCR market, by treatment, is bifurcated into quantitative PCR and digital PCR. The digital PCR segment held a larger share of the market in 2022 and is expected to register a higher CAGR in the market during 2022–2030. Digital PCR (dPCR) is a technique used to detect and quantify the amount of DNA or RNA present in a sample. dPCR is a highly precise method for detecting and quantifying nucleic acids that are both sensitive and repeatable. dPCR is an upgraded form of diagnostic technology for accurate nucleic acid measurement. dPCR offers benefits such as reduced error rate, less volume of reagents, lower experiment cost, and no reliance on standards and controls. Also, dPCR is highly quantitative as it does not depend on the relative fluorescence of the solution to determine the amount of amplified target DNA. This technique has several advantages over previous PCR procedures, including absolute quantification, increased sensitivity, and a more comprehensive dynamic range.

Many companies, such as Thermo Fisher Scientific Inc. and Bio-Rad Laboratories, Inc., offer various dPCR systems as well as kits and reagents for higher sensitivity, precision, and absolute quantification. In February 2023, Thermo Fisher Scientific Inc. introduced its new digital PCR research solution, the Applied Biosystems QuantStudio Absolute Q AutoRun dPCR suite. Furthermore, the increasing awareness of cutting-edge droplet digital PCR tests is projected to increase the application expansion. Thus, the benefits of digital PCR are expected to stimulate the growth of the segment during the forecast period.

dPCR and qPCR Market, by Treatment – 2022 and 2030

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Based on product, the dPCR and qPCR market is segmented into reagents & consumables, instruments, and software & services. In 2022, the reagents & consumables segment held the largest share of the market and is anticipated to grow at the fastest rate during 2022–2030. Reagents and consumables are essential parts of the dPCR and qPCR procedures. It includes buffers, probes, enzymes, dyes, vials, kits, panels, and others. Also, there are several kits available for gene expression analysis, SNP genotyping analysis, microRNA analysis, and others. The growing demand for earlier detection of disease; widespread use of consumables and reagents; and expanding demand for PCRs for healthcare, research, and other purposes have significantly fueled the market growth for the segment. Moreover, product launches and rising acceptance of technology are among the major factors contributing to the market growth for the segment. In July 2023, QIAGEN launched the CGT Viral Vector Lysis kit for the biopharmaceutical industry, expanding its range of dPCR kits and services. Therefore, these factors fuel the dPCR and qPCR market growth for the reagents & consumables segment.

Based on application, the dPCR and qPCR market is segmented into research application, clinical application, and forensic application. The clinical application segment held the largest market share in 2022 and is expected to register the highest CAGR during 2022–2030. Molecular biology techniques have revolutionized disease diagnosis and are now a crucial part of laboratory diagnostics. The dPCR and qPCR techniques are now being used in the diagnosis of many diseases, including diabetes, infectious diseases, cancer, and others. For instance, real-time PCR technology RIDA GENE kits are developed for the diagnosis of gastrointestinal infections, hospital-acquired infections (HAI), respiratory infections, sexually transmitted infections, and other parameters. As these molecular methods allow early, sensitive, and specific diagnosis, the clinical application segment is expected to witness growth over the forecast period.

Real-time PCR technologies have been used to detect mutation in genes, which helps in the diagnosis of cancer. dPCR also enables precise detection of tumor markers in cell-free DNA (cfDNA) samples. Furthermore, the rising prevalence of diseases such as thalassemia, hemophilia, sickle cell anemia, phenylketonuria, and various other conditions increases the demand for screening, which is carried out using qPCR and dPCR techniques. In addition, technological advancements are offering molecular markers for diagnosing and treating cancer. In April 2023, Thermo Fisher Scientific introduced 37 CE-IVD-marked real-time PCR assay kits for its QuantStudio Dx series of instruments to detect numerous infectious diseases.

Based on end user, the dPCR and qPCR market is categorized into hospitals and diagnostic centers, pharmaceutical and biotechnology companies, research laboratories and academic institutes, forensic laboratories, and clinical research organizations. The hospitals and diagnostic centers segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022–2030. Hospitals and diagnostic centers contribute a significant market share to the dPCR and qPCR market. Hospitals are the primary centers for a patient seeking highly advanced treatment under the guidance of much-trained personnel. dPCR and qPCR offer advantages such as high sensitivity and specificity, allowing early and accurate detection of pathogens, including bacteria, viruses, and fungi. In addition, hospitals offer advanced diagnosis and treatment options for patients to treat acute and chronic conditions, and the adoption of PCR techniques is much higher in hospitals and diagnostic centers as they provide healthcare facilities with specialized scientific equipment. Growing demand for early and efficient disease diagnosis and treatment, the increasing number of dPCR product launches for diagnostic applications, the advantages offered by dPCR in disease diagnosis (as compared to other PCR technologies), and growing awareness among the public associated with the benefits offered by both these technologies for clinical and disease diagnosis fuel the market growth.

Regional Analysis:

Based on geography, the dPCR and qPCR market is segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. North America held a significant share of the global market in 2022. The regional market growth is attributed to the increase in demand for innovative products from bio-analytical instrument manufacturers and PCR companies, presence of key market players, and extensive R&D conducted across various academic and research institutes. The increasing focus on advanced method incorporation in healthcare, government and private initiatives for promoting precision medicine, and rising funds from government and private bodies for genomic research also contribute to exceptional revenue generation for the dPCR and qPCR market in North America. Additionally, scientific advances made by various research groups in the region correspond to the growth and dominance of the region in the global market positioning.

Industry Developments and Future Opportunities:

Various initiatives taken by key players operating in the global dPCR and qPCR market are listed below:

  1. In July 2023, QIAGEN NV announced the expansion of its digital PCR (dPCR) offering for the development of cell and gene therapies in the biopharma industry. The company has partnered with Niba Labs to offer customized digital PCR assay design services to biopharma customers and also launched the new CGT Viral Vector Lysis Kit that enables a standardized workflow from cell lysates to absolute and precise quantification of viral titers for multiple serotypes.
  2. In June 2021, Bio-Rad Laboratories Inc. introduced their PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit, a sensitive, cost-effective, and accurate, instrument for detecting SARS-CoV-2 in a community's wastewater. The Centres for Disease Control and Prevention (CDC) recommends ddPCR techniques for wastewater testing, and the Environmental Protection Agency (EPA) has published the technology as a reliable way to quantify viruses in wastewater.

Competitive Landscape and Key Companies:

Abbott Laboratories, Thermo Fisher Scientific Inc., Takara Bio Inc., Qiagen NV, Lepu Medical Technology Beijing Co Ltd, F. Hoffmann-la Roche Ltd, Bio-rad Laboratories Inc., Agilent Technologies Inc, Standard Biotools Inc., and Genome Diagnostics Pvt Ltd are among the prominent players in the dPCR and qPCR market. These companies focus on introducing new high-tech products, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Treatment, Product, Application, End User, and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What was the estimated dPCR and qPCR market size in 2022?

The dPCR and qPCR market was valued at US$ 8,976.99 million in 2022.

What are the growth estimates for the dPCR and qPCR market till 2030?

The dPCR and qPCR market is expected to be valued at US$ 18,230.74 million in 2030.

What is dPCR and qPCR?

Digital PCR (dPCR) and quantitative PCR (qPCR) are two major types of PCR technologies. dPCR is a new technique utilized for DNA amplification and quantification that uses molecular counting protocol. dPCR is usually used to distinguish the expression of alleles, track viral infection to individual bacterial cells, quantify cancer genes, and detect fetal DNA in circulating blood. On the other hand, qPCR calculates PCR amplification simultaneously as the reaction proceeds.

Which segment is dominating the dPCR and qPCR market?

The global dPCR and qPCR market, based on product, is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR during the forecast period.

What are the driving and restraining factors for the dPCR and qPCR market?

The factors driving the growth of the dPCR and qPCR market include the increasing incidence of genetic and infectious diseases and technological advancements in PCR technologies. However, the high costs of PCR systems hamper the growth of the dPCR and qPCR market.

Who are the major players in the dPCR and qPCR market?

The dPCR and qPCR market majorly consists of the players, including Abbott Laboratories, Thermo Fisher Scientific Inc., Takara Bio Inc., Qiagen NV, Lepu Medical Technology Beijing Co Ltd, F. Hoffmann-la Roche Ltd, Bio-rad Laboratories Inc., Agilent Technologies Inc, Standard Biotools Inc., and Genome Diagnostics Pvt Ltd.

The List of Companies - dPCR and qPCR Market

  1. Abbott Laboratories
  2. Thermo Fisher Scientific Inc.
  3. Takara Bio Inc.
  4. Qiagen NV
  5. Standard Biotools Inc.
  6. Lepu Medical Technology Beijing Co Ltd
  7. F. Hoffmann-la Roche Ltd
  8. Bio-rad Laboratories Inc
  9. Agilent Technologies Inc
  10. Genome Diagnostics Pvt Ltd.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to dPCR and qPCR Market